NCT05337969View on ClinicalTrials.gov

The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Assessed.

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

March 31, 2016

Conditions
To Determine Bioequivalence Under Fed Conditions
Interventions
DRUG

Metformin and Vildagliptin 850/50 mg

50 mg Vildagliptin + 850 mg Metformin as single-dose per study period

All Listed Sponsors
lead

AET Laboratories Private Limited

INDUSTRY

NCT05337969 - The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Assessed. | Biotech Hunter | Biotech Hunter